Skip to main content

Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Publication ,  Journal Article
Townsley, S; Mohamed, Z; Guo, W; McKenna, J; Cleveland, B; LaBranche, C; Beaumont, D; Shen, X; Yates, NL; Pinter, A; Tomaras, GD; Ferrari, G ...
Published in: J Virol
October 1, 2016

UNLABELLED: Poxvirus prime-protein boost used in the RV144 trial remains the only immunization strategy shown to elicit a modest level of protection against HIV-1 acquisition in humans. Although neutralizing antibodies (NAb) were generated, they were against sensitive viruses, not the more resistant "tier 2" isolates that dominate circulating strains. Instead, risk reduction correlated with antibodies recognizing epitopes in the V1/V2 region of HIV-1 envelope glycoprotein (Env). Here, we examined whether tier 2 virus NAb and V1/V2-specific non-NAb could be elicited by a poxvirus prime-gp120 boost strategy in a rabbit model. We studied two clade B Envs that differ in multiple parameters, including tissue origin, neutralization sensitivity, and presence of the N197 (N7) glycan that was previously shown to modulate the exposure of conserved epitopes on Env. We demonstrate that immunized rabbits generated cross-reactive neutralizing activities against >50% of the tier 2 global HIV-1 isolates tested. Some of these activities were directed against the CD4 binding site (CD4bs). These rabbits also generated antibodies that recognized protein scaffolds bearing V1/V2 sequences from diverse HIV-1 isolates and mediated antibody-dependent cellular cytotoxicity. However, there are subtle differences in the specificities and the response rates of V1/V2-specific antibodies between animals immunized with different Envs, with or without the N7 glycan. These findings demonstrate that antibody responses that have been correlated with protection against HIV-1 acquisition in humans can be elicited in a preclinical model by a poxvirus prime-gp120 boost strategy and that improvements may be achievable by optimizing the nature of the priming and boosting immunogens. IMPORTANCE: The only vaccine approach shown to elicit any protective efficacy against HIV-1 acquisition is based on a poxvirus prime-protein boost regimen (RV144 Thai trial). Reduction of risk was associated with nonneutralizing antibodies targeting the V1/V2 loops of the envelope protein gp120. However, the modest efficacy (31.2%) achieved in this trial highlights the need to examine approaches and factors that may improve vaccine-induced responses, including cross-reactive neutralizing activities. We show here that rabbits immunized with a novel recombinant vaccinia virus prime-gp120 protein boost regimen generated antibodies that recognize protein scaffolds bearing V1/V2 sequences from diverse HIV-1 isolates and mediated antibody-dependent cellular cytotoxicity. Importantly, immunized rabbits also showed neutralizing activities against heterologous tier 2 HIV-1 isolates. These findings may inform the design of prime-boost immunization approaches and help improve the protective efficacy of candidate HIV-1 vaccines.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Virol

DOI

EISSN

1098-5514

Publication Date

October 1, 2016

Volume

90

Issue

19

Start / End Page

8644 / 8660

Location

United States

Related Subject Headings

  • Virology
  • Vaccinia virus
  • Vaccines, Synthetic
  • Vaccines, Subunit
  • Rabbits
  • Immunization
  • HIV-1
  • HIV Envelope Protein gp120
  • HIV Antibodies
  • Drug Carriers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Townsley, S., Mohamed, Z., Guo, W., McKenna, J., Cleveland, B., LaBranche, C., … Hu, S.-L. (2016). Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. J Virol, 90(19), 8644–8660. https://doi.org/10.1128/JVI.00853-16
Townsley, Samantha, Zeinab Mohamed, Wenjin Guo, Jennifer McKenna, Brad Cleveland, Celia LaBranche, David Beaumont, et al. “Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.J Virol 90, no. 19 (October 1, 2016): 8644–60. https://doi.org/10.1128/JVI.00853-16.
Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, et al. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. J Virol. 2016 Oct 1;90(19):8644–60.
Townsley, Samantha, et al. “Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.J Virol, vol. 90, no. 19, Oct. 2016, pp. 8644–60. Pubmed, doi:10.1128/JVI.00853-16.
Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, Beaumont D, Shen X, Yates NL, Pinter A, Tomaras GD, Ferrari G, Montefiori DC, Hu S-L. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. J Virol. 2016 Oct 1;90(19):8644–8660.

Published In

J Virol

DOI

EISSN

1098-5514

Publication Date

October 1, 2016

Volume

90

Issue

19

Start / End Page

8644 / 8660

Location

United States

Related Subject Headings

  • Virology
  • Vaccinia virus
  • Vaccines, Synthetic
  • Vaccines, Subunit
  • Rabbits
  • Immunization
  • HIV-1
  • HIV Envelope Protein gp120
  • HIV Antibodies
  • Drug Carriers